4//SEC Filing
ESHELMAN FREDRIC N 4
Accession 0001437749-22-024809
CIK 0001513818other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 5:00 PM ET
Size
12.9 KB
Accession
0001437749-22-024809
Insider Transaction Report
Form 4
Aravive, Inc.ARAV
Transactions
- Award
Series A Warrants (right to buy)
2022-10-24+8,153,060→ 8,153,060 total(indirect: See footnote)Exercise: $0.79→ Common stock (8,153,060 underlying) - Award
Series B Warrants (right to buy)
2022-10-24+8,153,060→ 8,153,060 total(indirect: See Footnote)Exercise: $0.79→ Common stock (8,153,060 underlying) - Award
Common Stock
2022-10-24$0.92/sh+16,306,120$15,000,000→ 25,517,889 total(indirect: See footnote)
ESHELMAN FREDRIC N
Director
Transactions
- Award
Series B Warrants (right to buy)
2022-10-24+8,153,060→ 8,153,060 total(indirect: See Footnote)Exercise: $0.79→ Common stock (8,153,060 underlying) - Award
Series A Warrants (right to buy)
2022-10-24+8,153,060→ 8,153,060 total(indirect: See footnote)Exercise: $0.79→ Common stock (8,153,060 underlying) - Award
Common Stock
2022-10-24$0.92/sh+16,306,120$15,000,000→ 25,517,889 total(indirect: See footnote)
Footnotes (5)
- [F1]On October 24, 2022, Aravive, Inc. (the "Company") agreed to issue approximately $41.5 million of securities including shares of its common stock and warrants (the "Warrants") to purchase shares of common stock in a private placement transaction (the "Private Placement") to certain investors, including Eshelman Ventures, LLC. The combined purchase price of each share of common stock and accompanying Warrants is $0.9199.
- [F2]The shares of common stock and Warrants reported herein are owned directly by Eshelman Ventures, LLC, an entity wholly owned by the reporting person, Dr. Fredric N. Eshelman. Dr. Eshelman is the Executive Chairman of the Company's Board of Directors and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F3]The Series A Warrants are exercisable at any time after the Authorized Share Increase (as defined below) and will expire on the date that is the later of (i) fifteen (15) months after the date of the Authorized Share Increase, or (ii) one (1) month after public announcement by or on behalf of the Company of the publication of top line data from the Company's Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer.
- [F4]In connection with the Private Placement, the Company has agreed to convene a special meeting of its stockholders or to seek written consent of the stockholders no later than 120 days following the closing of the Private Placement to seek approval of an increase in the number of the Company's authorized shares of common stock pursuant to an amendment to the Company's Certificate of Incorporation (such increase, the "Authorized Share Increase") to allow for full sufficient authorized and unissued shares of common stock for the full exercise of all of the Warrants and the shares of common stock issuable upon exercise thereof.
- [F5]The Series B Warrants are exercisable at any time after the Authorized Share Increase and will expire thirty (30) months after the Authorized Share Increase.
Documents
Issuer
Aravive, Inc.
CIK 0001513818
Entity typeother
Related Parties
1- filerCIK 0001033409
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 5:00 PM ET
- Size
- 12.9 KB